Thomas E. Mürdter - Concepedia

Author

Thomas E. Mürdter

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology ORCID

Also Known As

T E Mürdter, T MURDTER, T Mürdter, T. E. MURDTER, T. E. Mürdter, T. Mürdter, T.E. Mürdter, THOMAS MÜRDTER, Thomas E Mürdter, Thomas E Mürdter

179

Publications

4.4K

Citations

H-Index

100

Concepts

All Affiliations

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology University of Tübingen Robert Bosch Hospital Heidelberg University Saarland University

About

Thomas E. Mürdter is an author at Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	37	1.7K
2	Engineering	7	7	410
3	Health Sciences	5	5	303
4	Natural Sciences	1	1	28
5	Allergy	1	1	22

Thomas E. Mürdter

Publications

Citations

H-Index

Page 1

	Year	Citations
Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy Reinhold Kerb, Thomas E. Mürdter, Urs Giger-Pabst, Annals of Surgical Oncology	2013	364
Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine Tanja Richter, Thomas E. Mürdter, Georg Heinkele, Journal of Pharmacology and Experimental Therapeutics	2004	259
Fate of the Antibiotic Sulfamethoxazole and Its Two Major Human Metabolites in a Water Sediment Test Michael Radke, Christoph Lauwigi, Georg Heinkele, Environmental Science & Technology BioconcentrationEngineeringAntibiotic SulfamethoxazoleChemical ContaminantWastewater Treatment	2009	218
Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer Pilar H. Saladores, Thomas E. Mürdter, Diana Eccles, The Pharmacogenomics Journal Breast OncologyGynecologyPharmacotherapyEndocrine OncologyBody Mass Index	2014	197
P‐glycoprotein‐mediated intestinal and biliary digoxin transport in humans Siegfried Drescher, Hartmut Glaeser, Thomas E. Mürdter, Clinical Pharmacology & Therapeutics	2003	158
The influence of <i>CYP2B6</i>, <i>CYP2C9</i> and <i>CYP2D6</i> genotypes on the formation of the potent antioestrogen Z‐4‐hydroxy‐tamoxifen in human liver Janet K. Coller, Niels Krebsfaenger, Kathrin Klein, British Journal of Clinical Pharmacology	2002	131
Role of P-Glycoprotein Inhibition for Drug Interactions Sonja Eberl, Bertold Renner, Antje Neubert, Clinical Pharmacokinetics BiochemistryP-glycoprotein InhibitionMedicineGlycobiologyPharmacotherapy	2007	113
Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment Heiko van der Kuip, Thomas E. Mürdter, Maike Sonnenberg, BMC Cancer	2006	110
Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters Hiltrud Brauch, Werner Schroth, Matthew P. Goetz, Journal of Clinical Oncology Breast OncologyCyp2d6 GenotypeMedicineGeneticsGenetic Epidemiology	2012	101
Expression and function of β-glucuronidase in pancreatic cancer: potential role in drug targeting Bernhard Sperker, Ulrike Werner, Thomas E. Mürdter, Naunyn-Schmiedeberg s Archives of Pharmacology Drug TargetingPancreatic CancerBiochemistryPotential RoleMedicine	2000	86

Page 1